The Mixed-Lineage Leukemia (MLL) protein is a histone methyltransferase that is mutated in clinically and biologically distinctive subsets of acute leukemia. MLL normally associates with a cohort of highly conserved cofactors to form a macromolecular complex that includes menin, a product of the MEN1 tumor suppressor gene, which is mutated in heritable and sporadic endocrine tumors. We demonstrate here that oncogenic MLL fusion proteins retain an ability to stably associate with menin through a high-affinity, amino-terminal, conserved binding motif and that this interaction is required for the initiation of MLL-mediated leukemogenesis. Furthermore, menin is essential for maintenance of MLL-associated but not other oncogene induced myeloid transformation. Acute genetic ablation of menin reverses aberrant Hox gene expression mediated by MLL-menin promoter-associated complexes, and specifically abrogates the differentiation arrest and oncogenic properties of MLL-transformed leukemic blasts. These results demonstrate that a human oncoprotein is critically dependent on direct physical interaction with a tumor suppressor protein for its oncogenic activity, validate a potential target for molecular therapy, and suggest central roles for menin in altered epigenetic functions underlying the pathogenesis of hematopoietic cancers.
Introduction
MLL is a protooncogene that is targeted by chromosomal translocations in a diverse subset of hematologic disorders including acute lymphoid, myeloid, and biphenotypic leukemia and myelodysplastic syndrome, all of which are generally associated with a poor prognosis (DiMartino and Cleary, 1999 for review). As a consequence of acquired genetic aberrations in these disorders, the MLL protein is fused with one of more than 40 different partners to yield a diverse collection of chimeric fusion proteins (Mitterbauer- Wild-type MLL is a large, structurally complex protein whose transcriptional role is mediated in part through an ability to covalently modify chromatin, thus distinguishing it as one of only a few currently known chromatin-modifying enzymes that are directly mutated in human cancers (Schneider et (Yu et al., 1998) . In this capacity, MLL associates through its carboxy-terminal methylase domain with a cohort of proteins that are highly similar to components of the SET1 histone methyltransferase complexes of yeast and human, suggesting that all three macromolecular complexes employ an evolutionarily conserved biochemical mechanism to mediate their H3-K4-specific HMT activities (Yokoyama et al., 2004) . However, oncogenic mutations that create MLL fusion proteins in human leukemia result in disruption of the MLL macromolecular complex with consequent loss of the HMT domain and its associated conserved factors.
Menin is a highly specific partner for MLL proteins, as it is the only known member of the MLL macromolecular complex that is not shared with the SET1 complexes. Menin-containing MLL family HMT complexes were identified independently by immunopurification of menin and of MLL ( Here, we demonstrate that menin associates with MLL fusion proteins on HOX promoters in human leukemia cells, and is necessary for maintenance of HOX gene expression by MLL oncoproteins. Furthermore, menin is required for MLL-mediated transformation, and targeted acute inactivation of menin specifically reverses the differentiation arrest and oncogenic potential of MLL-transformed blasts. These studies support a unique and novel function for a tumor suppressor protein as a direct, essential cofactor for a distinctive group of oncoproteins in their roles as transcriptional misregulators of critical HOX target genes in acute leukemogenesis.
Results

MLL Oncoproteins Associate with Menin on HOX Gene Promoters in Human Leukemia Cells
To establish whether MLL oncoproteins associate with menin on target genes that are critical for MLL-mediated transformation, chromatin immunoprecipitation (ChIP) assays were performed using human ML-2 leukemia cells. These cells lack a normal MLL gene and thus exclusively express an MLL-AF6 fusion protein as a consequence of t(6;11) chromosomal translocation (Tanabe et al., 1996) , in contrast to control cells (REH) that carry no MLL chromosomal translocation and only express the processed MLL N and MLL C subunits (Figure 1A) . Immunoprecipitation of MLL-AF6 from ML-2 cells resulted in the coprecipitation of menin demonstrating that the two proteins associate with each other 
MLL Fusion Proteins Interact with Menin through Multiple Domains
To establish the structural requirements for MLL-menin interaction, a series of deletion mutations (Figure 2A ) was introduced into the MLL portion of MLL-ENL (ME) and evaluated in IP-Western blot analysis for their effects on the ability of ME to interact with endogenous menin. Immunoprecipitation of an initial series of FLAGtagged mutant ME proteins from nuclear extracts of transiently transfected cells revealed that a domain conferring strong interaction with endogenous menin resided within the first 331 amino acids of MLL ( Figure  2B ). A second, much weaker interaction domain was contained in a region spanning residues 640-1251 of MLL. More refined mutational analysis showed that the high-affinity interaction domain for menin localized within the first 35 amino acids of MLL ( Figure 2C ). Figures 4C and 4D) . Acute loss of menin in ME-transformed menin-floxed progenitors abrogated their clonogenic activity, whereas ME-transformed wild-type cells were unaffected ( Figure  4E ). The few colonies present in cultures of ME-transformed/CER-transduced Men1 floxed cells were small with diffuse morphology suggestive of a more differentiated phenotype in contrast to the large blasttype control colonies ( Figure 4F ). Other MLL oncogenetransformed cells (MA and MG) lost their clonogenic activity upon deletion of menin, as well ( Figure 4E ). Conversely, EH-transformed cells were unaffected by acute loss of menin and continued to produce colonies in methylcellulose medium ( Figure 4E ) with morphologies that were indistinguishable with or without Cre activation (data not shown). Therefore, menin is necessary for maintenance of transformation induced by MLL oncoproteins, in contrast to the EH oncoprotein, which appeared to be entirely independent of menin. Taken together, our results indicate a specific, as opposed to general, menin requirement for both the initiation and maintenance of transformation by MLL oncogenes.
Identification of a Conserved
Loss of Menin Relieves the Differentiation Block of MLL-Transformed Leukemic Blasts
The consequences of acute menin loss in MLL-transformed cells were further investigated in myeloid progenitors that were transformed by either the ME or MA oncogenes and coexpressed CER. Without inactivation of the Men1 gene, the cultures were comprised predominantly of Mac1 int cells with the morphologic features of blasts ( Figures 5A-5C ). Within 48 hr following acute Men1 deletion, the proportion of blasts was markedly reduced (e.g., 48% to 8% for ME/CER), and the cultures contained mostly Mac1 hi cells with mature or maturing cytologic features (Figures 5A-5C ). DNA content analysis showed that within 48 hr of Men1 deletion, there was an increase of the G0/G1 population and a reduction in S-G2/M phase cells ( Figure 5D ) and cells with metaphase chromatin (data not shown), consistent with the inability of Men1 null MLL-transformed cells to proliferate and generate CFU in culture ( Figure 4E ). MAtransformed cells also showed accumulation at G0/G1 phase while the vector control or wild-type cells did not (data not shown). Taken together, these analyses tion and maintenance of MLL-mediated oncogenic transformation. This does not reflect a generalized requirement for menin in myeloid progenitor transformation since the unrelated E2A-HLF oncoprotein is not dependent on menin for its oncogenic effects under identical experimental conditions. Therefore, menin is a specific and essential oncogenic cofactor for MLLmediated leukemogenesis.
The demonstration that menin associates with MLL oncoproteins on the HOXA9 promoter in leukemia cells suggested that they work together for transcriptional regulation of biologically relevant target genes, thereby providing a molecular basis for a menin requirement in MLL-mediated oncogenesis. Their colocalization on Hox promoters suggests that the menin requirement for transformation is unlikely to simply reflect its dominantnegative sequestration by MLL oncoproteins, although we cannot unequivocally rule out more complex scenarios that may in part involve menin sequestration. In support of a cofactor role for menin, expression of several Hoxa cluster genes is dramatically reduced in cells transduced with MLL oncoproteins lacking a menin binding motif and in MLL-transformed cells acutely depleted of menin. Hoxa9 in particular influences the incidence and/or phenotype of MLL leukemias, demonstrating that constitutive expression of Hox genes by menin/MLL fusion protein complexes is an important aspect of MLL leukemogenesis. Furthermore, a simple dominant-negative mechanism should not be affected by menin deletion, which would otherwise be redundant with MLL-mediated sequestration. Thus, menin appears to be a transcriptional and oncogenic cofactor that is required for transformation of myeloid progenitors as well as transcriptional misregulation of Hox genes by MLL oncoproteins. 
Dual Roles for Menin as a Tumor Suppressor and an Oncogenic Cofactor
Myeloid Progenitor Transformation Assays
Mouse bone marrow cells were harvested from leg bones, and cells expressing surface c-kit were purified by auto-MACS using a PEconjugated anti-c-kit antibody (2B8, BD) and anti-PE magnetic beads (Miltenyi Biotech). Purified cells were used for myeloid progenitor transformation assays as previously described (Lavau et al., 1997) with minor modifications. For secondary transductions, 10 5 cells were infected with retrovirus by spinoculation and cultured overnight in 2 ml of methylcellulose medium (M3231, Stemcell Technologies) containing SCF, IL-3, IL-6, and GM-CSF. Puromycin (1 g/ml) was added to the culture on the next day and the cells were plated in 6-well dishes. After 4-6 days, puromycin-resistant cells were replated in the presence of 1 nM of 4-OHT (Sigma) for induction of Cre-ER tam for further analysis. Transplantation of transduced progenitors into lethally irradiated, syngeneic recipients was performed as described previously (Lavau et al., 1997) , with the exception that donor C57BL/6 mice were transgenic for eGFP (Wright et al., 2001 ) and progenitors were incubated in RPMI 1640 medium supplemented with 20% FCS, 20% WEHI supernatant, 20 ng/ml SCF, 10 ng/ml IL-6, and 1mg/ml G418 for 5 days following spinoculation prior to transplantation. For DNA content analysis, ice-cold 70% ethanol (5 ml) was added with vortexing to cells suspended in PBS (100 l) followed by incubation on ice for at least 30 min. Cells were washed with PBS, suspended in 200 l, mixed with 10 l of 10 mg/ml RNase A, and then incubated at 37°C for 20 min. Following addition of 500 l of PI solution (0.1% trisodium citrate, 50 g/ml PI) and incubation for 10 min at 4°C, the cells were analyzed by flow cytometry.
Genotyping
Real-Time Quantitative PCR Analysis of Gene Expression
Total RNA was purified using an RNeasy mini kit (Qiagen), and 1 g was reverse-transcribed using an oligo-dT primer and Superscript First-Strand Synthesis System for RT-PCR (Invitrogen) according to the manufacturer's instructions. The reaction products were diluted (10×) with TE, and 2 l was subjected to real-time PCR, which was performed in triplicate using Taqman probes and the ABI Prism 7700 sequence detection system. Taqman probes for Hoxa7 (Mm00657963_m1), Hoxa9 (Mm00439364_m1), p27
Kip1
(Mm00438167_g1), and b-Actin (Mm00607939_m1) were purchased from Applied Biosystems. Expression levels of Hoxa7, Hoxa9, and p27
Kip1 relative to that of b-Actin were calculated using a standard curve and the relative quantitation method as described in ABI User Bulletin #2.
